Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Flt3L
- Development stage
- Unknown
- Lead developer
- Celldex Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral, Intravenous, Subcutaneous
01
Overview
Recombinant Flt3L (Fms-like tyrosine kinase 3 ligand) is a recombinant cytokine and growth factor that acts as an agonist of the FLT3 receptor (CD135). It stimulates the proliferation, differentiation, and mobilization of hematopoietic progenitor cells and dendritic cells, particularly conventional type-1 dendritic cells (cDC1) and plasmacytoid dendritic cells (pDC). Originally developed by Immunex (later acquired by Amgen) under the name Mobista, and subsequently developed by Celldex as CDX-301, recombinant Flt3L has been investigated in clinical trials for hematopoietic stem cell transplantation, cancer immunotherapy (such as in combination with vaccines or radiation therapy), and other immune-modulating indications. It is also widely manufactured and sold by various life science companies as a research-use-only (RUO) reagent for ex vivo cell culture and disease modeling.
- Brand names
- Mobista
- Other names
- FLFLT3LGFLT-3LGFLT 3LGFlt3 ligandFlt-3 ligandFlt 3 ligandFlt3-LFlt-3-LFlt 3-LFlt3LFlt-3LFlt 3LFms-like tyrosine kinase 3 ligandfms-related tyrosine kinase 3 ligandrecombinant human Flt3 ligandrecombinant human FMS-like tyrosine kinase-3 ligandrhuFlt3LrhuFlt-3LrhuFlt 3L
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on recombinant Flt3L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Flt3L.